168 related articles for article (PubMed ID: 9193344)
1. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.
Johansen MJ; Madden T; Mehra RC; Wood JG; Rondon G; Browne V; Newman RA; Champlin RE
J Clin Oncol; 1997 Apr; 15(4):1481-91. PubMed ID: 9193344
[TBL] [Abstract][Full Text] [Related]
2. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
Shea T; Graham M; Bernard S; Steagall A; Wiley J; Serody J; Brecher M; Bentley S; Johnston C; Vaisman A
Semin Oncol; 1995 Oct; 22(5 Suppl 12):80-5. PubMed ID: 7481867
[TBL] [Abstract][Full Text] [Related]
3. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ
J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Huizing MT; Giaccone G; van Warmerdam LJ; Rosing H; Bakker PJ; Vermorken JB; Postmus PE; van Zandwijk N; Koolen MG; ten Bokkel Huinink WW; van der Vijgh WJ; Bierhorst FJ; Lai A; Dalesio O; Pinedo HM; Veenhof CH; Beijnen JH
J Clin Oncol; 1997 Jan; 15(1):317-29. PubMed ID: 8996159
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells.
Schilder RJ; Johnson S; Gallo J; Kindsfather S; Rogers B; Bookman MA; Millenson MM; Boente M; Rosenblum N; Litwin S; Ozols RF
J Clin Oncol; 1999 Jul; 17(7):2198-207. PubMed ID: 10561276
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
Schilder RJ; Gallo JM; Millenson MM; Bookman MA; Weiner LM; Rogatko A; Rogers B; Padavic-Shallers K; Boente M; Rosenblum N; Adams AL; Ciccotto S; Ozols RF
J Clin Oncol; 2001 Feb; 19(4):1183-94. PubMed ID: 11181685
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
Socinski MA; Shea TC
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-45-S12-51. PubMed ID: 9331121
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
van Warmerdam LJ; Rodenhuis S; van der Wall E; Maes RA; Beijnen JH
Br J Cancer; 1996 Apr; 73(8):979-84. PubMed ID: 8611435
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer.
Fennelly DW; Aghajanian C; Shapiro F; O'Flaherty C; O'Connor K; Curtin JP; Crown JP; Hoskins WJ; Spriggs DR
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-26-S2-30. PubMed ID: 9045332
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
Marina NM; Rodman J; Shema SJ; Bowman LC; Douglass E; Furman W; Santana VM; Hudson M; Wilimas J; Meyer W
J Clin Oncol; 1993 Mar; 11(3):554-60. PubMed ID: 8445431
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
